Cancer Conference Update: ESMO Congress 2026 Review — Breast Cancer

Thursday, November 12, 2026
5:00 PM – 6:30 PM ET
Live CME/MOC-accredited webinar

Topics to Be Discussed

• Hormone Receptor-Positive Breast Cancer
• HER2-Positive Breast Cancer
• Triple-Negative Breast Cancer

Target Audience
This activity is intended for medical oncologists, breast surgeons, radiation oncologists and other healthcare professionals involved in the diagnosis and treatment of breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

• Evaluate recently presented clinical research findings to determine their relevance to the current management of localized or metastatic breast cancer.
• Appraise published efficacy and safety data from randomized clinical trials evaluating CDK4/6 inhibitors for HR-positive localized or metastatic breast cancer, and appropriately counsel patients regarding the optimal clinical use of these agents.
• Recognize the biological rationale for the development of agents targeting the PI3K/AKT/mTOR pathway, and recognize available data with FDA-approved treatments for patients with HR-positive metastatic breast cancer (mBC) with and without PIK3CA/AKT1/PTEN alterations.
• Understand the mechanism of action of, published research findings with and current and future clinical role for oral selective estrogen receptor degraders (SERDs) alone and in combination with other agents for patients with HR-positive mBC harboring ESR1 mutations.
• Analyze the scientific justification for, available data with and potential clinical role of oral SERDs as adjuvant treatment for patients with localized estrogen receptor-positive, HER2-negative breast cancer.
• Evaluate published research findings to effectively inform the selection and sequencing of available therapeutic agents and regimens for patients with HER2-positive localized or metastatic breast cancer.
• Review published research supporting the use of chemotherapy or antibody-drug conjugate (ADC) therapy in combination with anti-PD-1/PD-L1 antibodies for patients with localized or metastatic triple-negative breast cancer (TNBC), and use this information to make appropriate treatment recommendations.
• Interrogate published Phase III research documenting the efficacy of TROP2-directed ADC monotherapy for patients with mBC in order to determine the current clinical applicability of this approach.
• Assess the mechanisms of action of, early data with and ongoing clinical trials evaluating other novel agents and treatment strategies in development for localized and metastatic breast cancer.

CE Credit
CME and ABIM MOC credit information will be provided to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) 
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

American Board of Surgery (ABS) — Continuous Certification (CC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the learner to earn up to 1.5 Medical Knowledge MOC points toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. 

FACULTY
Prof Curigliano — Advisory Committees, Consulting Agreements and Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Exact Sciences Corporation, Gilead Sciences Inc, Lilly, Menarini Group, Novartis, Pfizer Inc, Roche Laboratories Inc; Data and Safety Monitoring Boards/Committees: Lilly, Pfizer Inc, Roche Laboratories Inc. Prof Dent — Advisory Committees and Consulting Agreements: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Lilly, MSD, Novartis, Pfizer Inc, Roche Laboratories Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Roche Laboratories Inc. Dr Jhaveri — Advisory Committees and Consulting Agreements: Arvinas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BBOT, BeOne, Bicycle Therapeutics, Blueprint Medicines, ConcertAI, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Halda Therapeutics, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Menarini Group, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Olema Oncology, Pfizer Inc, Precede Biosciences, RayzeBio, Regor Therapeutics, Relay Therapeutics, Scorpion Therapeutics, Stemline Therapeutics Inc, Zymeworks Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, BBOT, Bicycle Therapeutics, Blueprint Medicines, Eisai Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Pfizer Inc, Puma Biotechnology Inc, RayzeBio, Scorpion Therapeutics, Zymeworks Inc; Nonrelevant Financial Relationships: Breast Cancer Research Foundation, Fred’s Team, Manhasset Women’s Coalition Against Breast Cancer, National Cancer Institute (BRIMM/UG3 CA239861 Award).

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Catalyst Pharmaceuticals Inc, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, and Verastem Inc. 

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Celcuity, Daiichi Sankyo Inc, Lilly, and Stemline Therapeutics Inc.

Please click the link to register for this live event directly on Zoom. Once you register, Zoom will send a confirmation email with your individual link to access the event. Please keep that confirmation email handy. If you do not receive it, contact our support team at meetings@researchtopractice.com.